In Q2 2025, Amicus Therapeutics Inc (0HF9.L) reported revenues of $154.69 million, marking a significant increase of 23.5% quarter-over-quarter and 22.12% year-over-year. This growth was largely underpinned by the continued success of their main product, Galafold, which remains a crucial component of their revenue stream. Despite this positive development, the company recorded a net loss of $24.42 million, which reflects an ongoing struggle with profitability and rising operating expenses that amounted to $145.39 million.
Management stressed the importance of their ongoing investment in research and development, with R&D expenses amounting to $60.85 million for the quarter. The management remains optimistic about future growth prospects as they continue to advance their pipeline products, including treatments for Pompe disease and CLN3, aiming for significant breakthroughs in rare disease therapeutics. Nevertheless, the need to engineer cost efficiencies and improve operational sustainability is clear as the company grapples with a net income margin of -15.79% for the quarter.